论文部分内容阅读
目的探讨应用草酸铂和伊立替康、氟尿嘧啶治疗晚期结直肠癌的临床疗效以及毒副反应情况,为临床用药提高参考价值。方法将118例晚期肠癌患者分为联合治疗组和对照组,各59例,联合治疗组采用动脉介入加静脉用药进行草酸铂和伊立替康、氟尿嘧啶药物应用,对照组单纯采用静脉用药进行草酸铂和伊立替康、氟尿嘧啶药物应用。比较两组患者的临床疗效和毒副反有无差别。治疗时间为2个治疗周期,每个周期四周,连续治疗2个周期后观察临床疗效及毒副反应情况。结果两组的不良反应以恶心呕吐、白细胞减少、贫血最为常见,联合组分别占32.7%,29.6%,11.2%,均明显低于常规治疗组的68.%,57.1%,37.6%。联合治疗组的客观有效率(ORR)为75%,显著高于对照组40%率,结且差别有统计学意义(p<0.05)。结论动脉介入联合静脉草酸铂和伊立替康、氟尿嘧啶治疗晚期复发或肝转移性结直肠癌临床疗效可靠。
Objective To investigate the clinical efficacy and adverse reactions of oxaliplatin, irinotecan and fluorouracil in the treatment of advanced colorectal cancer and to improve the reference value for clinical use. Methods One hundred and eighty-one patients with advanced colorectal cancer were divided into combined treatment group and control group, 59 cases in each group. The combination therapy group received intravenous administration of oxaliplatin, irinotecan and fluorouracil by arterial intervention and intravenous administration. The control group received intravenous administration of oxalic acid Platinum and irinotecan, fluorouracil drug applications. Compare the clinical efficacy of the two groups of patients and no difference in toxicity. Treatment time is 2 treatment cycles, each cycle of four weeks, continuous treatment of two cycles after observation of clinical efficacy and toxicity. Results The adverse reactions of nausea and vomiting, leukopenia and anemia were the most common in the two groups. The combined group accounted for 32.7%, 29.6% and 11.2% respectively, which were significantly lower than 68%, 57.1% and 37.6% of the conventional treatment group. The objective response rate (ORR) was 75% in the combination group, which was significantly higher than that in the control group (40%), with a statistically significant difference (p <0.05). Conclusion Arterial intervention with intravenous oxaliplatin and irinotecan, fluorouracil in the treatment of advanced recurrent or metastatic colorectal cancer is clinically effective.